INDEPENDENT THINKING. WHOLE-FOOD LIVING.NO ANIMALS / NO OIL
THENANODIET
← THE STUDY LIBRARY

Systematic review / meta-analysis / 2022

A systematic review of 417 human reports found no evidence supporting the classification of soyfoods or isoflavones as endocrine disruptors.

Researchers systematically reviewed evidence from inception through January 2021 examining soy or isoflavone intake and endocrine endpoints across 417 reports (229 observational studies, 157 clinical studies, and 32 systematic reviews and meta-analyses). Isoflavone intake was found not to adversely affect thyroid function, breast or endometrial tissue, estrogen levels in women, or testosterone, estrogen, or sperm and semen parameters in men. Menstrual cycle length was slightly increased without preventing ovulation, and data on in utero exposure and children were reassuring though limited. The authors concluded that evidence does not support classifying isoflavones as endocrine disruptors.

Study type
Technical systematic review of observational and clinical data
Who was studied
Humans across 417 reports (229 observational, 157 clinical, 32 SRMAs)
What was measured
Endocrine-related endpoints including thyroid, reproductive tissues and hormones

THE PAPER

Neither soyfoods nor isoflavones warrant classification as endocrine disruptors: a technical review of the observational and clinical data.

Messina M, Mejia SB, Cassidy A, Duncan A, Kurzer M, Nagato C, Ronis M, Rowland I, Sievenpiper J, Barnes S. Crit Rev Food Sci Nutr, 2022.

PubMed 33775173 ↗DOI 10.1080/10408398.2021.1895054 ↗

Nutrients & adequacyOther health

This note is written from the study's published abstract. It summarizes what the authors reported; it is not medical advice and does not replace reading the full paper.